Published in J Virol on August 04, 2010
The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency. Future Microbiol (2011) 1.13
Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)--an update. Curr Opin Virol (2013) 0.99
Viral latency locus augments B-cell response in vivo to induce chronic marginal zone enlargement, plasma cell hyperplasia, and lymphoma. Blood (2013) 0.97
Murine gamma-herpesvirus immortalization of fetal liver-derived B cells requires both the viral cyclin D homolog and latency-associated nuclear antigen. PLoS Pathog (2011) 0.92
Latency locus complements MicroRNA 155 deficiency in vivo. J Virol (2013) 0.88
Quantitative analysis of the bidirectional viral G-protein-coupled receptor and lytic latency-associated nuclear antigen promoter of Kaposi's sarcoma-associated herpesvirus. J Virol (2012) 0.78
Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation. J Virol (2015) 0.76
KSHV Latency Locus Cooperates with Myc to Drive Lymphoma in Mice. PLoS Pathog (2015) 0.76
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med (1995) 21.16
Germinal-center organization and cellular dynamics. Immunity (2007) 5.62
HIV disease: fallout from a mucosal catastrophe? Nat Immunol (2006) 5.08
Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity (2001) 4.92
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
PI3 kinase signals BCR-dependent mature B cell survival. Cell (2009) 4.43
Herpesvirus latency confers symbiotic protection from bacterial infection. Nature (2007) 4.27
Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature (1995) 4.10
Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol (2002) 3.75
Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity (2006) 3.74
A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med (2003) 3.10
Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol (2001) 2.87
The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol (2009) 2.80
Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. J Exp Med (1996) 2.71
Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J Virol (2002) 2.71
Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity (1995) 2.69
The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients. J Exp Med (1996) 2.67
Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science (1999) 2.61
Antigen-driven B cell differentiation in vivo. J Exp Med (1993) 2.35
Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). J Virol (2001) 2.31
HIV-associated lymphomas and gamma-herpesviruses. Blood (2008) 2.27
Germinal centers without T cells. J Exp Med (2000) 2.25
Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2001) 2.19
Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol (2003) 2.05
Neoteny in lymphocytes: Rag1 and Rag2 expression in germinal center B cells. Science (1996) 2.03
The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity (1997) 2.00
Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol (1996) 1.97
Pathogenesis of an infectious mononucleosis-like disease induced by a murine gamma-herpesvirus: role for a viral superantigen? J Exp Med (1997) 1.88
Endemic Burkitt's lymphoma: a polymicrobial disease? Nat Rev Microbiol (2005) 1.83
The gammaherpesvirus 68 latency-associated nuclear antigen homolog is critical for the establishment of splenic latency. J Virol (2003) 1.70
Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest. J Virol (2006) 1.68
The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. J Biol Chem (2004) 1.64
The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus transactivates the telomerase reverse transcriptase promoter. J Biol Chem (2001) 1.48
EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog (2007) 1.46
Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA. Proc Natl Acad Sci U S A (2006) 1.43
Inhibition of NF-kappaB activation in vivo impairs establishment of gammaherpesvirus latency. PLoS Pathog (2007) 1.39
The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc Natl Acad Sci U S A (1995) 1.35
The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest (2006) 1.26
CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med (1997) 1.26
The physiologic role of CD19 cytoplasmic tyrosines. Immunity (2002) 1.25
The superantigen-homologous viral immediate-early gene ie14/vsag in herpesvirus saimiri-transformed human T cells. J Virol (1997) 1.24
CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J Immunol (2003) 1.20
CD19 function in early and late B cell development. II. CD19 facilitates the pro-B/pre-B transition. J Immunol (2003) 1.18
Role of B-cell proliferation in the establishment of gammaherpesvirus latency. J Virol (2005) 1.15
Role of Notch signal transduction in Kaposi's sarcoma-associated herpesvirus gene expression. J Virol (2005) 1.11
Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas. J Virol (2010) 1.07
Transcriptional coactivation of c-Jun by the KSHV-encoded LANA. Blood (2003) 1.06
Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region. J Immunol (1999) 1.05
The effect of deleting p110delta on the phenotype and function of PTEN-deficient B cells. J Immunol (2008) 1.04
Ex vivo stimulation of B cells latently infected with gammaherpesvirus 68 triggers reactivation from latency. J Virol (2005) 1.00
A role for herpesvirus saimiri orf14 in transformation and persistent infection. J Virol (1998) 0.99
Tissue specificity of the Kaposi's sarcoma-associated herpesvirus latent nuclear antigen (LANA/orf73) promoter in transgenic mice. J Virol (2002) 0.98
Epstein-Barr virus LMP2A enhances B-cell responses in vivo and in vitro. J Virol (2006) 0.96
A novel human B cell subpopulation representing the initial germinal center population to express AID. Blood (2006) 0.94
Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo. Blood (2008) 0.90
Murine gammaherpesvirus 68 LANA is essential for virus reactivation from splenocytes but not long-term carriage of viral genome. J Virol (2010) 0.89
Distinct roles of phosphoinositide-3 kinase and phospholipase Cgamma2 in B-cell receptor-mediated signal transduction. Mol Cell Biol (2006) 0.81
Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J Virol (2002) 2.71
EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res (2008) 2.46
Moving forward in HIV-associated cancer. J Clin Oncol (2014) 2.14
Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood (2006) 1.83
In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell (2007) 1.68
SYBR green-based real-time quantitative PCR assay for detection of West Nile Virus circumvents false-negative results due to strain variability. J Clin Microbiol (2004) 1.64
Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol (2006) 1.63
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood (2010) 1.60
Toll-like receptor signaling controls reactivation of KSHV from latency. Proc Natl Acad Sci U S A (2009) 1.55
Pre-micro RNA signatures delineate stages of endothelial cell transformation in Kaposi sarcoma. PLoS Pathog (2009) 1.53
Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res (2006) 1.49
Early experience after developing a pathology laboratory in Malawi, with emphasis on cancer diagnoses. PLoS One (2013) 1.48
Faster quantitative real-time PCR protocols may lose sensitivity and show increased variability. Nucleic Acids Res (2005) 1.47
More on HIV-associated Kaposi's sarcoma. N Engl J Med (2008) 1.38
Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood (2007) 1.34
Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol (2006) 1.32
Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. Proc Natl Acad Sci U S A (2012) 1.32
Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis (2013) 1.31
Real-time quantitative PCR analysis of viral transcription. Methods Mol Biol (2005) 1.29
Interferon-γ production by neutrophils during bacterial pneumonia in mice. Am J Respir Crit Care Med (2010) 1.29
The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res (2004) 1.28
The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest (2006) 1.26
Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. Int J Cancer (2007) 1.21
Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood (2005) 1.14
Regulation and autoregulation of the promoter for the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Biol Chem (2004) 1.14
Potential pitfalls in microRNA profiling. Wiley Interdiscip Rev RNA (2012) 1.14
Role of Notch signal transduction in Kaposi's sarcoma-associated herpesvirus gene expression. J Virol (2005) 1.11
Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. Blood (2009) 1.09
Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas. J Virol (2010) 1.07
mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res (2013) 1.04
Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS Pathog (2013) 1.04
Expression profile of microRNAs in Epstein-Barr virus-infected AGS gastric carcinoma cells. J Virol (2013) 1.02
Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood (2011) 1.01
Comparison of the Rta/Orf50 transactivator proteins of gamma-2-herpesviruses. J Virol (2004) 1.00
Baboon model for West Nile virus infection and vaccine evaluation. Virology (2006) 0.99
Tissue specificity of the Kaposi's sarcoma-associated herpesvirus latent nuclear antigen (LANA/orf73) promoter in transgenic mice. J Virol (2002) 0.98
Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication. J Virol (2009) 0.97
Liposomal daunorubicin as treatment for Kaposi's sarcoma. Int J Nanomedicine (2007) 0.97
Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. J Infect Dis (2011) 0.97
Viral latency locus augments B-cell response in vivo to induce chronic marginal zone enlargement, plasma cell hyperplasia, and lymphoma. Blood (2013) 0.97
Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog (2012) 0.95
Latent Kaposi's sarcoma-associated herpesvirus infection of monocytes downregulates expression of adaptive immune response costimulatory receptors and proinflammatory cytokines. J Virol (2012) 0.95
Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. Am J Pathol (2011) 0.94
Methylene blue photoinactivation of RNA viruses. Antiviral Res (2004) 0.92
Novel Kaposi's sarcoma-associated herpesvirus homolog in baboons. J Virol (2003) 0.91
Disruption of LANA in rhesus rhadinovirus generates a highly lytic recombinant virus. J Virol (2009) 0.90
Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A. Virology (2012) 0.90
An important role for mitochondrial antiviral signaling protein in the Kaposi's sarcoma-associated herpesvirus life cycle. J Virol (2014) 0.90
Tousled-like kinases modulate reactivation of gammaherpesviruses from latency. Cell Host Microbe (2013) 0.89
Ribosomal protein S6 interacts with the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2011) 0.88
De novo generation of CD4 T cells against viruses present in the host during immune reconstitution. Blood (2004) 0.88
Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features. Am J Clin Pathol (2008) 0.88
Latency locus complements MicroRNA 155 deficiency in vivo. J Virol (2013) 0.88
General and target-specific RNA binding properties of Epstein-Barr virus SM posttranscriptional regulatory protein. J Virol (2009) 0.87
The open chromatin landscape of Kaposi's sarcoma-associated herpesvirus. J Virol (2013) 0.87
Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr (2012) 0.87
Profiling of pre-micro RNAs and microRNAs using quantitative real-time PCR (qPCR) arrays. J Vis Exp (2010) 0.87
Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid. Clin Infect Dis (2009) 0.87
Promoter switching allows simultaneous transcription of LANA and K14/vGPCR of Kaposi's sarcoma-associated herpesvirus. Virology (2006) 0.87
Development of a fluorescence-based assay to screen antiviral drugs against Kaposi's sarcoma associated herpesvirus. Mol Cancer Ther (2007) 0.86
Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US, 2000 to 2011. Infect Agent Cancer (2013) 0.86
Methylene blue photoinactivation abolishes West Nile virus infectivity in vivo. Antiviral Res (2005) 0.83
Cytokine homologs of human gammaherpesviruses. J Interferon Cytokine Res (2011) 0.83
Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy. J Clin Invest (2016) 0.82
Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. AIDS (2014) 0.81
Kaposi's sarcoma in the era of HAART-an update on mechanisms, diagnostics and treatment. AIDS Rev (2005) 0.80
Viral latent proteins as targets for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) induced lymphoma. Curr Drug Targets Infect Disord (2003) 0.80
Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase. J Virol (2013) 0.80
Genome-wide real-time PCR for West Nile virus reduces the false-negative rate and facilitates new strain discovery. J Virol Methods (2010) 0.80
Nuclear factor kappa B pathway associated biomarkers in AIDS defining malignancies. Int J Cancer (2011) 0.80
Fusion between hematopoietic and epithelial cells in adult human intestine. PLoS One (2013) 0.80
Enhanced cytotoxicity without internuclear spread of adenovirus upon cell fusion by measles virus glycoproteins. J Virol (2005) 0.79
A naturally occurring fatal case of Herpesvirus papio 2 pneumonia in an infant baboon (Papio hamadryas anubis). J Am Assoc Lab Anim Sci (2006) 0.78
Rapalogs in viral cancers. Expert Opin Investig Drugs (2012) 0.78
Efficiency clustering for low-density microarrays and its application to QPCR. BMC Bioinformatics (2010) 0.78
Quantitative analysis of the bidirectional viral G-protein-coupled receptor and lytic latency-associated nuclear antigen promoter of Kaposi's sarcoma-associated herpesvirus. J Virol (2012) 0.78
Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma. Leuk Lymphoma (2014) 0.78
AIDS related malignancies in Brazil. Curr Opin Oncol (2007) 0.77
Poisson factor models with applications to non-normalized microRNA profiling. Bioinformatics (2013) 0.77
Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas. Leuk Lymphoma (2013) 0.76
Reply to P. De Paoli et al. J Clin Oncol (2014) 0.75
Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. J Acquir Immune Defic Syndr (2016) 0.75
Kaposi's sarcoma in Malawi: a continued problem for HIV-positive and HIV-negative individuals. AIDS (2017) 0.75
Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation. AIDS (2017) 0.75
Chlamydia Trachomatis Seroprevalence and Ultrasound Diagnosed Uterine Fibroids in a Large Population of Young African-American Women. Am J Epidemiol (2017) 0.75